Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher

Showing results (281-290 of 6,822) with videos related to

Pageof 683
Sort By:
Nature Reviews. Drug Discovery|October 2, 2018
Painkilling anti-NGF antibodies stage phase III comebackAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
FDA approves second BCMA-targeted CAR-T cell therapyAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
R&D budgets boom, but success rates falterAsher Mullard
Nature Reviews. Drug Discovery|March 16, 2022
Reflections on 10 years of the FDA's breakthrough therapy designationAsher Mullard
The Psychohistory Review|January 1, 1979
Non-psychoanalytic approaches to national socialismH Asher
Nature Reviews. Drug Discovery|October 2, 2019
PCSK9-lowering RNAi contender clears first phase III trialAsher Mullard
Nature Reviews. Drug Discovery|December 12, 2025
Betting on β-catenin inhibitors in oncologyAsher Mullard
Nature Reviews. Drug Discovery|November 5, 2025
Novartis pays US$12 billion for Avidity's lead antibody-oligonucleotide drugsAsher Mullard
Nature Reviews. Drug Discovery|November 6, 2025
Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spotAsher Mullard
Nature Reviews. Drug Discovery|May 3, 2011
Dual fronts poised to transform melanoma therapyAsher Mullard
Pageof 683

Showing results (281-290 of 6,822) with videos related to

Sort By:
Pageof 683
Nature Reviews. Drug Discovery|October 2, 2018
Painkilling anti-NGF antibodies stage phase III comebackAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
FDA approves second BCMA-targeted CAR-T cell therapyAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
R&D budgets boom, but success rates falterAsher Mullard
Nature Reviews. Drug Discovery|March 16, 2022
Reflections on 10 years of the FDA's breakthrough therapy designationAsher Mullard
The Psychohistory Review|January 1, 1979
Non-psychoanalytic approaches to national socialismH Asher
Nature Reviews. Drug Discovery|October 2, 2019
PCSK9-lowering RNAi contender clears first phase III trialAsher Mullard
Nature Reviews. Drug Discovery|December 12, 2025
Betting on β-catenin inhibitors in oncologyAsher Mullard
Nature Reviews. Drug Discovery|November 5, 2025
Novartis pays US$12 billion for Avidity's lead antibody-oligonucleotide drugsAsher Mullard
Nature Reviews. Drug Discovery|November 6, 2025
Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spotAsher Mullard
Nature Reviews. Drug Discovery|May 3, 2011
Dual fronts poised to transform melanoma therapyAsher Mullard
Pageof 683